DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Argininosuccinate is an investigational drug.
There have been 4 clinical trials for Argininosuccinate. The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2016.
The most common disease conditions in clinical trials are Ischemia, Sarcoma, and Mesothelioma. The leading clinical trial sponsors are Polaris Group, University of Colorado, Denver, and Washington University School of Medicine.
There are three hundred and eighty-two US patents protecting this investigational drug and two international patents.
Recent Clinical Trials for Argininosuccinate
|ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma||Polaris Pharmaceuticals, Inc.||Phase 2|
|ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma||Washington University School of Medicine||Phase 2|
|Ph 2/3 Study in Subjects With MPM w/Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin||Polaris Group||Phase 2/Phase 3|
Top disease conditions for Argininosuccinate
Top clinical trial sponsors for Argininosuccinate
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Argininosuccinate||See Pricing||Methods of expressing products in mammalian cells||INTREXON CEU, INC. (Blacksburg, VA)||See Pricing|
|Argininosuccinate||See Pricing||Methods and compositions for multiplex PCR||LIFE TECHNOLOGIES CORPORATION (Carlsbad, CA)||See Pricing|
|Argininosuccinate||See Pricing||Peptides and peptide/active compound conjugates for renal targeting||MERCK PATENT GMBH (Darmstadt, DE)||See Pricing|
|Argininosuccinate||See Pricing||Compositions of engineered human arginases and methods for treating cancer||AERase, Inc. (Austin, TX)||See Pricing|
|Argininosuccinate||See Pricing||Methods and compositions for multiplex PCR||Life Technologies Corporation (Carlsbad, CA)||See Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Argininosuccinate||World Intellectual Property Organization (WIPO)||2012027533||2030-08-25||See Pricing|
|Argininosuccinate||European Patent Office||2702170||2031-04-28||See Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|